Literature DB >> 15735032

Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells.

Marc Hotfilder1, Silja Röttgers, Annegret Rosemann, André Schrauder, Martin Schrappe, Rob Pieters, Heribert Jürgens, Jochen Harbott, Josef Vormoor.   

Abstract

Open questions in the pathogenesis of childhood acute lymphoblastic leukemia (ALL) are which hematopoietic cell is target of the malignant transformation and whether primitive stem cells contribute to the leukemic clone. Although good-prognosis ALL is thought to originate in a lymphoid progenitor, it is unclear if this applies to high-risk ALL. Therefore, immature CD34(+)CD19(-) bone marrow cells from 8 children with ALL/t(9;22) and 12 with ALL/t(4;11) were purified and analyzed by fluorescence in situ hybridization, reverse transcription-PCR (RT-PCR), and colony assays. Fifty-six percent (n = 8, SD 31%) and 68% (n = 12, SD 26%) of CD34(+)CD19(-) cells in ALL/t(9;22) and ALL/t(4;11), respectively, carried the translocation. In addition, 5 of 168 (3%) and 22 of 228 (10%) myeloerythroid colonies expressed BCR/ABL and MLL/AF4. RT-PCR results were confirmed by sequence analysis. Interestingly, in some patients with ALL/t(4;11), alternative splicing was seen in myeloid progenitors compared with the bulk leukemic population, suggesting that these myeloid colonies might be part of the leukemic cell clone. Fluorescence in situ hybridization analysis, however, shows that none of these myeloid colonies (0 of 41 RT-PCR-positive colonies) originated from a progenitor cell that carries the leukemia-specific translocation. Thus, leukemic, translocation-positive CD34(+)CD19(-) progenitor/stem cells that were copurified by cell sorting were able to survive in these colony assays for up to 28 days allowing amplification of the respective fusion transcripts by sensitive RT-PCR. In conclusion, we show that childhood high-risk ALL/t(9;22) and t(4;11) originate in a primitive CD34(+)CD19(-) progenitor/stem cell without a myeloerythroid developmental potential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735032     DOI: 10.1158/0008-5472.CAN-04-1356

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Authors:  Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Tontanai Numbenjapon; Jennifer Bennitt; Daniel Kim; David Smith; George McNamara; Zaid Al-Kadhimi; Joseph Rosenthal; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

2.  Bafilomycin A1 targets patient-derived CD34+CD19+ leukemia stem cells.

Authors:  Li Xu; Na Yuan; Hong Liu; Yixuan Fang; Chaorong Ge; Fei Xu; Ni An; Wen Wei; Lei Li; Li Ji; Xiaoying Zhang; Jiahao Meng; Suping Zhang; Yun Zhao; Zixing Chen; Suning Chen; Depei Wu; Jianrong Wang
Journal:  Haematologica       Date:  2019-05-16       Impact factor: 9.941

Review 3.  Chromosomal translocations among the healthy human population: implications in oncogenesis.

Authors:  Mridula Nambiar; Sathees C Raghavan
Journal:  Cell Mol Life Sci       Date:  2012-09-05       Impact factor: 9.261

4.  Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.

Authors:  Albert G Tsai; Haihui Lu; Sathees C Raghavan; Markus Muschen; Chih-Lin Hsieh; Michael R Lieber
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

5.  Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.

Authors:  Cecily A Bennett; Amanda C Winters; Nisha N Barretto; Charles S Hemenway
Journal:  Leuk Res       Date:  2009-02-20       Impact factor: 3.156

Review 6.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

Review 7.  Role of Pericellular Matrix in the Regulation of Cancer Stemness.

Authors:  Sofia Avnet; Margherita Cortini
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

8.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

Review 9.  Understanding the cancer stem cell.

Authors:  S Bomken; K Fiser; O Heidenreich; J Vormoor
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

10.  Cancer Stem Cells: From Bench to Bedside.

Authors:  Richard J Jones; William Matsui
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.